Robeco Institutional Asset Management B.V. increased its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 73.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 465,032 shares of the company's stock after buying an additional 197,585 shares during the period. Robeco Institutional Asset Management B.V.'s holdings in Teva Pharmaceutical Industries were worth $8,380,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently bought and sold shares of the company. New Covenant Trust Company N.A. acquired a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter worth $28,000. EntryPoint Capital LLC acquired a new stake in Teva Pharmaceutical Industries in the first quarter worth about $30,000. UMB Bank n.a. grew its stake in shares of Teva Pharmaceutical Industries by 555.6% during the third quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock worth $44,000 after acquiring an additional 2,067 shares during the last quarter. Claro Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at about $52,000. Finally, Beach Investment Counsel Inc. PA purchased a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $48,000. Hedge funds and other institutional investors own 54.05% of the company's stock.
Teva Pharmaceutical Industries Price Performance
NYSE TEVA traded down $0.34 during trading on Friday, hitting $17.16. The stock had a trading volume of 3,832,702 shares, compared to its average volume of 9,281,917. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. The firm has a 50 day moving average price of $17.98 and a 200 day moving average price of $17.07. Teva Pharmaceutical Industries Limited has a twelve month low of $8.55 and a twelve month high of $19.31.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.04. Teva Pharmaceutical Industries had a negative net margin of 5.73% and a positive return on equity of 41.43%. The firm had revenue of $4.33 billion for the quarter, compared to the consensus estimate of $4.08 billion. As a group, research analysts predict that Teva Pharmaceutical Industries Limited will post 2.34 earnings per share for the current year.
Analysts Set New Price Targets
Several equities research analysts have recently commented on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, October 21st. Barclays boosted their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, October 23rd. UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a "buy" rating in a research note on Tuesday, September 3rd. Finally, StockNews.com raised Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $19.67.
Check Out Our Latest Stock Report on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Company Profile
(
Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Recommended Stories
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
